WENTWORTH TIMOTHY C 4

What Happened
Timothy C. Wentworth, a director of Quest Diagnostics (DGX), was granted 1,142 restricted stock units (RSUs) on May 20, 2026. The Form 4 shows an acquisition price of $0.00 for the award (total reported value $0 on the form), which reflects a compensation grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (timely filing).
• Reported transaction: Grant/award (code A) of 1,142 shares at $0.00.
• Footnote F1: The transaction represents an award of restricted stock units.
• Footnote F2: The reported amount includes shares acquired via dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors since the last Form 4 filing.
• Shares owned after the transaction: not specified in the provided filing details.
• No indication in the filing of a 10b5-1 plan, immediate sale, or tax-withholding share surrender.

Context
This was an equity compensation award (RSUs) to a board member—common for director pay—and not an open-market purchase or sale. Awards reported with an acquisition price of $0 typically reflect grant accounting; their economic value depends on vesting conditions and the company’s stock price when/if they vest.